{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T20:46:27Z","timestamp":1793652387457,"version":"4.5.1"},"reference-count":106,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T00:00:00Z","timestamp":1745366400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T00:00:00Z","timestamp":1745366400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Psychopharmacology"],"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Rationale<\/jats:title>\n                    <jats:p>Psilocybin is a potentially paradigm-shifting depression intervention. We conducted a systematic review and meta-analysis of psilocybin-for-depression randomized controlled trials (RCTs).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Systematically assess harm reporting, risk of bias, action mechanism specification, and incremental therapeutic effect sizes in the psilocybin-for-depression RCT literature.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Assessed databases included PsycINFO, CINAHL, Embase, Medline, Web of Science, and Scopus. Search terms \u201cPsilocybin\u201d or \u201cPsychedelic\u201d were paired with \u201cDepression\u201d, and \"Randomized Controlled Trial\" or \u201cRCT\u201d.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      We identified\n                      <jats:italic>k<\/jats:italic>\n                      \u2009=\u20099 RCTs (\n                      <jats:italic>k<\/jats:italic>\n                      \u2009=\u200910 subgroups) involving\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009602 participants (56% psilocybin). Five studies had low\/very low harm quality reporting, opposed to two with high. Most studies demonstrated a high risk of bias. Therapeutic mechanisms of action (MoAs) were discussed in varying detail but rarely assessed in original publications. Psilocybin was moderately superior to controls at reducing depression (\n                      <jats:italic>g<\/jats:italic>\n                      \u2009=\u20090.62; 95% CI\u2009=\u20090.27, 0.98). Effects were heterogenous (\u03c4\u2009=\u2009.47). Smaller studies evidenced stronger effects that favored psilocybin (Egger\u2019s\n                      <jats:italic>b<\/jats:italic>\n                      0\u2009=\u20093.63,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u2009.014). Almost all studies documented financial conflicts of interests.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Psilocybin demonstrates significant depression reduction relative to controls. However, researchers, clinicians, and stakeholders should consider several contextual factors. Effects were moderate and attenuated in larger and better-controlled studies. Harms reporting and risk of bias was high, though partly driven by unique challenges of psilocybin research. MoAs were variably specified but rarely assessed; suggesting it is unclear how depression is reduced. We advise researchers conduct RCTs with active control conditions, larger samples, and include MoA assessments. Independent RCTs from researchers without financial conflicts of interest are needed.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00213-025-06788-w","type":"journal-article","created":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T05:07:24Z","timestamp":1745384844000},"page":"2139-2157","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Incremental efficacy systematic review and meta-analysis of psilocybin-for-depression RCTs"],"prefix":"10.1007","volume":"242","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-4436-8500","authenticated-orcid":false,"given":"Nicholas C.","family":"Borgogna","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tyler","family":"Owen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Petrovitch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob","family":"Vaughn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A. L.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr","given":"Louis A.","family":"Pagano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen L.","family":"Aita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin D.","family":"Hill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,23]]},"reference":[{"key":"6788_CR1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.books.9780890425787","volume-title":"Diagnostic and Statistical Manual of Mental Disorders, 5th Edition: DSM-5-TR","author":"American Psychiatric Association","year":"2022","unstructured":"American Psychiatric Association (2022) Diagnostic and Statistical Manual of Mental Disorders, 5th Edition: DSM-5-TR. American Psychiatric Association"},{"key":"6788_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/S12954-019-0308-4\/FIGURES\/3","volume":"16","author":"T Anderson","year":"2019","unstructured":"Anderson T, Petranker R, Christopher A, Rosenbaum D, Weissman C, Dinh-Williams LA, Hui K, Hapke E (2019) Psychedelic microdosing benefits and challenges: An empirical codebook. Harm Reduct J 16:1\u201310. https:\/\/doi.org\/10.1186\/S12954-019-0308-4\/FIGURES\/3","journal-title":"Harm Reduct J"},{"key":"6788_CR3","unstructured":"Automeris LLC. (2024). Web Plot Digitizer. Automeris.Io. https:\/\/automeris.io\/WebPlotDigitizer.html"},{"key":"6788_CR4","doi-asserted-by":"publisher","first-page":"e2449026","DOI":"10.1001\/JAMANETWORKOPEN.2024.49026","volume":"7","author":"AL Back","year":"2024","unstructured":"Back AL, Freeman-Young TK, Morgan L, Sethi T, Baker KK, Myers S, McGregor BA, Harvey K, Tai M, Kollefrath A, Thomas BJ, Sorta D, Kaelen M, Kelmendi B, Gooley TA (2024) Psilocybin therapy for clinicians with symptoms of depression from frontline care during the COVID-19 pandemic: A randomized clinical trial. JAMA Network Open 7:e2449026. https:\/\/doi.org\/10.1001\/JAMANETWORKOPEN.2024.49026","journal-title":"JAMA Network Open"},{"key":"6788_CR5","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1159\/000320118","volume":"79","author":"P Bech","year":"2010","unstructured":"Bech P (2010) Struggle for subtypes in primary and secondary depression and their mode-specific treatment or healing. Psychother Psychosom 79:331\u2013338. https:\/\/doi.org\/10.1159\/000320118","journal-title":"Psychother Psychosom"},{"key":"6788_CR6","doi-asserted-by":"crossref","unstructured":"Beck AT, Steer RA, Brown GK (1996) Beck Depression Inventory II (BDI-II). In: Manual for the Beck Depression Inventory\u2013II. Psychological Corporation","DOI":"10.1037\/t00742-000"},{"key":"6788_CR7","volume-title":"Beck depression inventory amended","author":"AT Beck","year":"1993","unstructured":"Beck AT, Steer RA (1993) Beck depression inventory amended. In manual for the beck depression inventory, The Psychological Corporation Inc"},{"key":"6788_CR8","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1001\/JAMA.289.4.454","volume":"289","author":"JE Bekelman","year":"2003","unstructured":"Bekelman JE, Li Y, Gross CP (2003) Scope and impact of financial conflicts of interest in biomedical research: A systematic review. JAMA 289:454\u2013465. https:\/\/doi.org\/10.1001\/JAMA.289.4.454","journal-title":"JAMA"},{"key":"6788_CR9","unstructured":"Borenstein M, Hedges L, Higgins J, Rothstein H (2013) Comprehensive Meta-Analysis. Englewood, NJ: Bisostat"},{"key":"6788_CR10","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1177\/02698811221116926\/ASSET\/IMAGES\/LARGE\/10.1177_02698811221116926-FIG1.JPEG","volume":"36","author":"JJ Breeksema","year":"2022","unstructured":"Breeksema JJ, Kuin BW, Kamphuis J, van den Brink W, Vermetten E, Schoevers RA (2022) Adverse events in clinical treatments with serotonergic psychedelics and MDMA: A mixed-methods systematic review. J Psychopharmacol 36:1100\u20131117. https:\/\/doi.org\/10.1177\/02698811221116926\/ASSET\/IMAGES\/LARGE\/10.1177_02698811221116926-FIG1.JPEG","journal-title":"J Psychopharmacol"},{"key":"6788_CR11","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/J.CPR.2005.07.003","volume":"26","author":"AC Butler","year":"2006","unstructured":"Butler AC, Chapman JE, Forman EM, Beck AT (2006) The empirical status of cognitive- behavioral therapy: A review of meta-analyses. Clin Psychol Rev 26:17\u201331. https:\/\/doi.org\/10.1016\/J.CPR.2005.07.003","journal-title":"Clin Psychol Rev"},{"key":"6788_CR12","doi-asserted-by":"publisher","first-page":"R10","DOI":"10.1093\/HMG\/DDAA115","volume":"29","author":"N Cai","year":"2020","unstructured":"Cai N, Choi KW, Fried EI (2020) Reviewing the genetics of heterogeneity in depression: operationalizations, manifestations and etiologies. Hum Mol Genet 29:R10\u2013R18. https:\/\/doi.org\/10.1093\/HMG\/DDAA115","journal-title":"Hum Mol Genet"},{"key":"6788_CR13","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/S2215-0366(16)30065-7","volume":"3","author":"RL Carhart-Harris","year":"2016","unstructured":"Carhart-Harris RL, Bolstridge M, Rucker J, Day CMJ, Erritzoe D, Kaelen M, Bloomfield M, Rickard JA, Forbes B, Feilding A, Taylor D, Pilling S, Curran VH, Nutt DJ (2016) Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. The Lancet Psychiatry 3:619\u2013627. https:\/\/doi.org\/10.1016\/S2215-0366(16)30065-7","journal-title":"The Lancet Psychiatry"},{"key":"6788_CR14","doi-asserted-by":"publisher","unstructured":"Carhart-Harris R, Giribaldi B, Watts R, Baker-Jones M, Murphy-Beiner A, Murphy R, Martell J, Blemings A, Erritzoe D, Nutt D (2021) Trial of psilocybin versus escitalopram for depression. N Engl J Med 384:1402\u20131411. https:\/\/doi.org\/10.1056\/NEJMoa2032994","DOI":"10.1056\/NEJMoa2032994"},{"key":"6788_CR15","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/S0140-6736(17)32802-7","volume":"16","author":"A Cipriani","year":"2018","unstructured":"Cipriani A, Furukawa TA, Salanti G, Chaimani A, Atkinson LZ, Ogawa Y, Leucht S, Ruhe HG, Turner EH, Higgins JPT, Egger M, Takeshima N, Hayasaka Y, Imai H, Shinohara K, Tajika A, Ioannidis JPA, Geddes JR (2018) Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: A systematic review and network meta-analysis. Lancet 16:420\u2013429. https:\/\/doi.org\/10.1016\/S0140-6736(17)32802-7","journal-title":"Lancet"},{"key":"6788_CR16","doi-asserted-by":"publisher","unstructured":"Cristea IA, Fried EI, Kaiser T, Hengartner MP, Turner EH, Naudet F (2024) Maintaining rational expectations about psychedelic interventions. BMJ 385 https:\/\/doi.org\/10.1136\/bmj-2023-078084","DOI":"10.1136\/bmj-2023-078084"},{"key":"6788_CR17","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1002\/WPS.20249","volume":"14","author":"P Cuijpers","year":"2015","unstructured":"Cuijpers P, Cristea IA (2015) What if a placebo effect explained all the activity of depression treatments? World Psychiatry 14:311. https:\/\/doi.org\/10.1002\/WPS.20249","journal-title":"World Psychiatry"},{"key":"6788_CR18","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1001\/JAMAPSYCHIATRY.2020.3285","volume":"78","author":"AK Davis","year":"2021","unstructured":"Davis AK, Barrett FS, May DG, Cosimano MP, Sepeda ND, Johnson MW, Finan PH, Griffiths RR (2021) Effects of psilocybin-assisted therapy on major depressive disorder: A randomized clinical trial. JAMA Psychiat 78:481\u2013489. https:\/\/doi.org\/10.1001\/JAMAPSYCHIATRY.2020.3285","journal-title":"JAMA Psychiat"},{"key":"6788_CR19","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1038\/s41591-022-01744-z","volume":"28","author":"RE Daws","year":"2022","unstructured":"Daws RE, Timmermann C, Giribaldi B, Sexton JD, Wall MB, Erritzoe D, Roseman L, Nutt D, Carhart-Harris R (2022) Increased global integration in the brain after psilocybin therapy for depression. Nat Med 28:844\u2013851. https:\/\/doi.org\/10.1038\/s41591-022-01744-z","journal-title":"Nat Med"},{"key":"6788_CR20","volume-title":"SCL-90: Administration, scoring & procedures manual for the R(evised) version and other instruments of the psychopathology rating scale series","author":"LR Derogatis","year":"1977","unstructured":"Derogatis LR (1977) SCL-90: Administration, scoring & procedures manual for the R(evised) version and other instruments of the psychopathology rating scale series. Johns Hopkins University School of Medicine"},{"key":"6788_CR21","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1177\/0269881120986422","volume":"35","author":"RG dos Santos","year":"2021","unstructured":"dos Santos RG, Hallak JEC, Baker G, Dursun S (2021) Hallucinogenic\/psychedelic 5HT2A receptor agonists as rapid antidepressant therapeutics: Evidence and mechanisms of action. J Psychopharmacol 35:453\u2013458. https:\/\/doi.org\/10.1177\/0269881120986422","journal-title":"J Psychopharmacol"},{"key":"6788_CR22","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1111\/J.0006-341X.2000.00455.X","volume":"56","author":"S Duval","year":"2000","unstructured":"Duval S, Tweedie R (2000) Trim and fill: A simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics 56:455\u2013463. https:\/\/doi.org\/10.1111\/J.0006-341X.2000.00455.X","journal-title":"Biometrics"},{"key":"6788_CR23","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1097\/00005053-195812000-00006","volume":"127","author":"B Eisner","year":"1958","unstructured":"Eisner B, Cohen S (1958) Psychotherapy with lysergic acid diethylamide. J Nerv Ment Dis 127:528\u2013539","journal-title":"J Nerv Ment Dis"},{"key":"6788_CR24","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1080\/02791072.2019.1593561","volume":"51","author":"J Fadiman","year":"2019","unstructured":"Fadiman J, Korb S (2019) Might microdosing psychedelics be safe and beneficial? An initial exploration. J Psychoactive Drugs 51:118\u2013122. https:\/\/doi.org\/10.1080\/02791072.2019.1593561","journal-title":"J Psychoactive Drugs"},{"key":"6788_CR25","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/S00406-004-0542-X\/METRICS","volume":"255","author":"M Feijo De Mello","year":"2005","unstructured":"Feijo De Mello M, De Jesus Mari J, Bacaltchuk J, Verdeli H, Neugebauer R (2005) A systematic review of research findings on the efficacy of interpersonal therapy for depressive disorders. Eur Arch Psychiatry Clin Neurosci 255:75\u201382. https:\/\/doi.org\/10.1007\/S00406-004-0542-X\/METRICS","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"6788_CR26","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1037\/a0015808","volume":"40","author":"CJ Ferguson","year":"2009","unstructured":"Ferguson CJ (2009) An effect size primer: A guide for clinicians and researchers. Prof Psychol Res Pract 40:532\u2013538. https:\/\/doi.org\/10.1037\/a0015808","journal-title":"Prof Psychol Res Pract"},{"key":"6788_CR27","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1037\/PHA0000490","volume":"29","author":"C Fogg","year":"2021","unstructured":"Fogg C, Michaels TI, de la Salle S, Jahn ZW, Williams MT (2021) Ethnoracial health disparities and the ethnopsychopharmacology of psychedelic-assisted psychotherapies. Exp Clin Psychopharmacol 29:539\u2013554. https:\/\/doi.org\/10.1037\/PHA0000490","journal-title":"Exp Clin Psychopharmacol"},{"key":"6788_CR28","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1093\/IJNP\/PYAC074","volume":"26","author":"JJ Gattuso","year":"2023","unstructured":"Gattuso JJ, Perkins D, Ruffell S, Lawrence AJ, Hoyer D, Jacobson LH, Timmermann C, Castle D, Rossell SL, Downey LA, Pagni BA, Galv\u00e3o-Coelho NL, Nutt D, Sarris J (2023) Default mode network modulation by psychedelics: A systematic review. Int J Neuropsychopharmacol 26:155\u2013188. https:\/\/doi.org\/10.1093\/IJNP\/PYAC074","journal-title":"Int J Neuropsychopharmacol"},{"key":"6788_CR29","doi-asserted-by":"publisher","first-page":"112749","DOI":"10.1016\/J.PSYCHRES.2020.112749","volume":"284","author":"SB Goldberg","year":"2020","unstructured":"Goldberg SB, Pace BT, Nicholas CR, Raison CL, Hutson PR (2020) The experimental effects of psilocybin on symptoms of anxiety and depression: A meta-analysis. Psychiatry Res 284:112749. https:\/\/doi.org\/10.1016\/J.PSYCHRES.2020.112749","journal-title":"Psychiatry Res"},{"key":"6788_CR30","doi-asserted-by":"publisher","unstructured":"Goodwin GM, Aaronson ST, Alvarez O, Arden PC, Baker A, Bennett JC, Bird C, Blom RE, Brennan C, Brusch D, Burke L, Campbell-Coker K, Carhart-Harris R, Cattell J, Daniel A, DeBattista C, Dunlop BW, Eisen K, Feifel D, \u2026 Malievskaia E (2022) Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England J Med 387:1637\u20131648 https:\/\/doi.org\/10.1056\/NEJMOA2206443\/SUPPL_FILE\/NEJMOA2206443_DATA- SHARING.PDF","DOI":"10.1056\/NEJMOA2206443\/SUPPL_FILE\/NEJMOA2206443_DATA"},{"key":"6788_CR31","doi-asserted-by":"publisher","unstructured":"Goodwin GM, Aaronson ST, Alvarez O, Atli M, Bennett JC, Croal M, DeBattista C, Dunlop BW, Feifel D, Hellerstein DJ, Husain MI, Kelly JR, Lennard-Jones MR, Licht RW, Marwood L, Mistry S, P\u00e1len\u00ed\u010dek T, Redjep O, Repantis D, \u2026 Malievskaia E (2023) Single- dose psilocybin for a treatment-resistant episode of major depression: Impact on patient-reported depression severity, anxiety, function, and quality of life. J Affect Disord 327:120\u2013127. https:\/\/doi.org\/10.1016\/J.JAD.2023.01.108","DOI":"10.1016\/J.JAD.2023.01.108"},{"key":"6788_CR32","doi-asserted-by":"publisher","unstructured":"Goodwin GM, Aaronson ST, Alvarez O, Carhart-Harris R, Chai-Rees J, Croal M, DeBattista C, Dunlop BW, Feifel D, Hellerstein DJ, Husain MI, Kelly JR, Kirlic N, Licht RW, Marwood L, Meyer TD, Mistry S, Nowakowska A, P\u00e1len\u00ed\u010dek T, \u2026 Malievskaia E (2025) The role of the psychedelic experience in psilocybin treatment for treatment-resistant depression. J Affect Disord 372:523\u2013532 https:\/\/doi.org\/10.1016\/J.JAD.2024.12.061","DOI":"10.1016\/J.JAD.2024.12.061"},{"key":"6788_CR33","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1001\/ARCHGENPSYCHIATRY.2010.116","volume":"68","author":"CS Grob","year":"2011","unstructured":"Grob CS, Danforth AL, Chopra GS, Hagerty M, McKay CR, Halberstad AL, Greer GR (2011) Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer. Arch Gen Psychiatry 68:71\u201378. https:\/\/doi.org\/10.1001\/ARCHGENPSYCHIATRY.2010.116","journal-title":"Arch Gen Psychiatry"},{"key":"6788_CR34","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1177\/02698811211073759\/ASSET\/IMAGES\/LARGE\/10.1177_02698811211073759-FIG2.JPEG","volume":"36","author":"N Gukasyan","year":"2022","unstructured":"Gukasyan N, Davis AK, Barrett FS, Cosimano MP, Sepeda ND, Johnson MW, Griffiths RR (2022) Efficacy and safety of psilocybin-assisted treatment for major depressive disorder: Prospective 12-month follow-up. J Psychopharmacol 36:151\u2013158. https:\/\/doi.org\/10.1177\/02698811211073759\/ASSET\/IMAGES\/LARGE\/10.1177_02698811211073759-FIG2.JPEG","journal-title":"J Psychopharmacol"},{"key":"6788_CR35","doi-asserted-by":"publisher","first-page":"115531","DOI":"10.1016\/J.PSYCHRES.2023.115531","volume":"329","author":"S Haikazian","year":"2023","unstructured":"Haikazian S, Chen-Li DCJ, Johnson DE, Fancy F, Levinta A, Husain MI, Mansur RB, McIntyre RS, Rosenblat JD (2023) Psilocybin-assisted therapy for depression: A systematic review and meta-analysis. Psychiatry Res 329:115531. https:\/\/doi.org\/10.1016\/J.PSYCHRES.2023.115531","journal-title":"Psychiatry Res"},{"key":"6788_CR36","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1017\/S0033291721004207","volume":"52","author":"W Hall","year":"2022","unstructured":"Hall W (2022) Why was early therapeutic research on psychedelic drugs abandoned? Psychol Med 52:26\u201331. https:\/\/doi.org\/10.1017\/S0033291721004207","journal-title":"Psychol Med"},{"key":"6788_CR37","doi-asserted-by":"publisher","first-page":"108641","DOI":"10.1016\/J.PHARMTHERA.2024.108641","volume":"258","author":"ZR Haniff","year":"2024","unstructured":"Haniff ZR, Bocharova M, Mantingh T, Rucker JJ, Velayudhan L, Taylor DM, Young AH, Aarsland D, Vernon AC, Thuret S (2024) Psilocybin for dementia prevention? The potential role of psilocybin to alter mechanisms associated with major depression and neurodegenerative diseases. Pharmacol Ther 258:108641. https:\/\/doi.org\/10.1016\/J.PHARMTHERA.2024.108641","journal-title":"Pharmacol Ther"},{"key":"6788_CR38","doi-asserted-by":"publisher","DOI":"10.1037\/17335-000","volume-title":"Acceptance and commitment therapy: An experiential approach to behavior change","author":"SC Hayes","year":"2012","unstructured":"Hayes SC, Strosahl K, Wilson KG (2012) Acceptance and commitment therapy: An experiential approach to behavior change. Guilford Press"},{"key":"6788_CR39","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1007\/BF01825267\/METRICS","volume":"40","author":"A Heffter","year":"1898","unstructured":"Heffter A (1898) Ueber Pellote - Beitr\u00e4ge zur chemischen und pharmakologischen Kenntniss der Cacteen Zweite Mittheilung. Archiv F\u00fcr Exp Pathol Pharmakol 40:385\u2013429. https:\/\/doi.org\/10.1007\/BF01825267\/METRICS","journal-title":"Archiv F\u00fcr Exp Pathol Pharmakol"},{"key":"6788_CR40","doi-asserted-by":"publisher","unstructured":"Higgins JPT, Savovi\u0107 J, Page MJ, Elbers RG, Sterne JAC (2019) Assessing risk of bias in a randomized trial. In Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (Eds.), Cochrane Handbook for Systematic Reviews of Interventions (Second Edi). John Wiley & Sons, Ltd. https:\/\/doi.org\/10.1002\/9781119536604.CH8","DOI":"10.1002\/9781119536604.CH8"},{"key":"6788_CR41","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1002\/CPT.2057","volume":"109","author":"F Holze","year":"2021","unstructured":"Holze F, Liechti ME, Hutten NRPW, Mason NL, Dolder PC, Theunissen EL, Duthaler U, Feilding A, Ramaekers JG, Kuypers KPC (2021) Pharmacokinetics and pharmacodynamics of lysergic acid diethylamide microdoses in healthy participants. Clin Pharmacol Ther 109:658\u2013666. https:\/\/doi.org\/10.1002\/CPT.2057","journal-title":"Clin Pharmacol Ther"},{"key":"6788_CR42","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1177\/02698811231180276\/ASSET\/IMAGES\/LARGE\/10.1177_02698811231180276-FIG2.JPEG","volume":"37","author":"OR Hovmand","year":"2023","unstructured":"Hovmand OR, Poulsen ED, Arnfred S, Storeb\u00f8 OJ (2023) Risk of bias in randomized clinical trials on psychedelic medicine: A systematic review. J Psychopharmacol 37:649\u2013659. https:\/\/doi.org\/10.1177\/02698811231180276\/ASSET\/IMAGES\/LARGE\/10.1177_02698811231180276-FIG2.JPEG","journal-title":"J Psychopharmacol"},{"key":"6788_CR43","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/J.NEUBIOREV.2017.12.012","volume":"86","author":"ZM Ign\u00e1cio","year":"2018","unstructured":"Ign\u00e1cio ZM, Calixto AV, da Silva RH, Quevedo J, R\u00e9us GZ (2018) The use of quetiapine in the treatment of major depressive disorder: Evidence from clinical and experimental studies. Neurosci Biobehav Rev 86:36\u201350. https:\/\/doi.org\/10.1016\/J.NEUBIOREV.2017.12.012","journal-title":"Neurosci Biobehav Rev"},{"key":"6788_CR44","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1176\/APPI.AJP.2010.09091379","volume":"167","author":"T Insel","year":"2010","unstructured":"Insel T, Cuthbert B, Garvey M, Heinssen R, Pine DS, Quinn K, Sanislow C, Wang P (2010) Research domain criteria (RDoC): Toward a new classification framework for research on mental disorders. Am J Psychiatry 167:748\u2013751. https:\/\/doi.org\/10.1176\/APPI.AJP.2010.09091379","journal-title":"Am J Psychiatry"},{"key":"6788_CR45","doi-asserted-by":"publisher","first-page":"e124","DOI":"10.1371\/journal.pmed.0020124","volume":"2","author":"JPA Ioannidis","year":"2005","unstructured":"Ioannidis JPA (2005) Why most published research findings are false. PLoS Medicine 2:e124. https:\/\/doi.org\/10.1371\/journal.pmed.0020124","journal-title":"PLoS Medicine"},{"key":"6788_CR46","doi-asserted-by":"publisher","first-page":"781","DOI":"10.7326\/0003-4819-141-10-200411160-00009\/ASSET\/IMAGES\/9TT5.JPG","volume":"141","author":"JPA Ioannidis","year":"2004","unstructured":"Ioannidis JPA, Evans SJW, G\u00f8tzsche PC, O\u2019Neill RT, Altman DG, Schulz K, Moher D (2004) Better reporting of harms in randomized trials: An extension of the CONSORT statement. Ann Intern Med 141:781\u2013788. https:\/\/doi.org\/10.7326\/0003-4819-141-10-200411160-00009\/ASSET\/IMAGES\/9TT5.JPG","journal-title":"Ann Intern Med"},{"key":"6788_CR47","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1007\/S13311-017-0542-Y\/METRICS","volume":"14","author":"MW Johnson","year":"2017","unstructured":"Johnson MW, Griffiths RR (2017) Potential therapeutic effects of psilocybin. Neurotherapeutics 14:734\u2013740. https:\/\/doi.org\/10.1007\/S13311-017-0542-Y\/METRICS","journal-title":"Neurotherapeutics"},{"key":"6788_CR48","doi-asserted-by":"publisher","first-page":"259","DOI":"10.5706\/nph201212007","volume":"14","author":"G Juhasz","year":"2012","unstructured":"Juhasz G, Eszlari N, Pap D, Gonda X (2012) Cultural differences in the development and characteristics of depression. Neuropsychopharmacol Hung 14:259\u2013265. https:\/\/doi.org\/10.5706\/nph201212007","journal-title":"Neuropsychopharmacol Hung"},{"key":"6788_CR49","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41380-024-02875-0","volume":"2024","author":"J Jungwirth","year":"2024","unstructured":"Jungwirth J, von Rotz R, Dziobek I, Vollenweider FX, Preller KH (2024) Psilocybin increases emotional empathy in patients with major depression. Mol Psychiatry 2024:1\u20138. https:\/\/doi.org\/10.1038\/s41380-024-02875-0","journal-title":"Mol Psychiatry"},{"key":"6788_CR50","first-page":"S147","volume":"5","author":"A Kalali","year":"2002","unstructured":"Kalali A, Bech P, Williams JBW, Kobak KA, Lipschitz J, Engelhardt N, Evans K, Olin J, Pearson J, Rothman M (2002) The new GRID HAM-D: pilot testing and international field trials. Int J Neuropsychopharmacol 5:S147","journal-title":"Int J Neuropsychopharmacol"},{"key":"6788_CR51","doi-asserted-by":"publisher","first-page":"10544","DOI":"10.1523\/JNEUROSCI.3007-12.2013","volume":"33","author":"M Kometer","year":"2013","unstructured":"Kometer M, Schmidt A, J\u00e4ncke L, Vollenweider FX (2013) Activation of serotonin 2A receptors underlies the psilocybin-induced effects on \u03b1 Oscillations, N170 visual-evoked potentials, and visual hallucinations. J Neurosci 33:10544\u201310551. https:\/\/doi.org\/10.1523\/JNEUROSCI.3007-12.2013","journal-title":"J Neurosci"},{"key":"6788_CR52","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1177\/0269881119857204\/ASSET\/IMAGES\/LARGE\/10.1177_0269881119857204-FIG1.JPEG","volume":"33","author":"KPC Kuypers","year":"2019","unstructured":"Kuypers KPC, Ng L, Erritzoe D, Knudsen GM, Nichols CD, Nichols DE, Pani L, Soula A, Nutt D (2019) Microdosing psychedelics: More questions than answers? An overview and suggestions for future research. J Psychopharmacol 33:1039\u20131057. https:\/\/doi.org\/10.1177\/0269881119857204\/ASSET\/IMAGES\/LARGE\/10.1177_0269881119857204-FIG1.JPEG","journal-title":"J Psychopharmacol"},{"key":"6788_CR53","unstructured":"Lamotte S (2022) Severe depression eased by single dose of synthetic \u2018magic mushroom.\u2019 CNN. https:\/\/www.cnn.com\/2022\/11\/02\/health\/psilocybin-magic-mushroom-depression- wellness\/index.html"},{"key":"6788_CR54","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1007\/BF01923627\/METRICS","volume":"24","author":"L Lewin","year":"1888","unstructured":"Lewin L (1888) Ueber Anhalonium Lewinii. Archiv F\u00fcr Exp Pathol Pharmakol 24:401\u2013411. https:\/\/doi.org\/10.1007\/BF01923627\/METRICS","journal-title":"Archiv F\u00fcr Exp Pathol Pharmakol"},{"key":"6788_CR55","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1007\/S12264-021-00638-3","volume":"37","author":"Z Li","year":"2021","unstructured":"Li Z, Ruan M, Chen J, Fang Y (2021) Major depressive disorder: Advances in neuroscience research and translational applications. Neurosci Bull 37:863\u2013880. https:\/\/doi.org\/10.1007\/S12264-021-00638-3","journal-title":"Neurosci Bull"},{"key":"6788_CR56","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/J.JAD.2021.09.041","volume":"296","author":"NX Li","year":"2022","unstructured":"Li NX, Hu YR, Chen WN, Zhang B (2022) Dose effect of psilocybin on primary and secondary depression: a preliminary systematic review and meta-analysis. J Affect Disord 296:26\u201334. https:\/\/doi.org\/10.1016\/J.JAD.2021.09.041","journal-title":"J Affect Disord"},{"key":"6788_CR57","doi-asserted-by":"publisher","unstructured":"Lovibond SH, Lovibond PF (1995) The structure of negative emotional states: comparison of the depression anxiety stress scales (DASS) with the beck depression and anxiety inventories.\u00a0Behav Res Ther 33:335\u2013343. https:\/\/doi.org\/10.1016\/0005-7967(94)00075-U","DOI":"10.1016\/0005-7967(94)00075-U"},{"key":"6788_CR58","doi-asserted-by":"publisher","first-page":"q1798","DOI":"10.1136\/BMJ.Q1798","volume":"386","author":"E Mahase","year":"2024","unstructured":"Mahase E (2024) MDMA assisted therapy: Three papers are retracted as FDA rejects PTSD application. BMJ 386:q1798. https:\/\/doi.org\/10.1136\/BMJ.Q1798","journal-title":"BMJ"},{"key":"6788_CR59","doi-asserted-by":"publisher","first-page":"335252","DOI":"10.3389\/FPHAR.2018.00256\/BIBTEX","volume":"9","author":"TC Malone","year":"2018","unstructured":"Malone TC, Mennenga SE, Guss J, Podrebarac SK, Owens LT, Bossis AP, Belser AB, Agin- Liebes G, Bogenschutz MP, Ross S (2018) Individual experiences in four cancer patients following psilocybin-assisted psychotherapy. Front Pharmacol 9:335252. https:\/\/doi.org\/10.3389\/FPHAR.2018.00256\/BIBTEX","journal-title":"Front Pharmacol"},{"key":"6788_CR60","doi-asserted-by":"publisher","unstructured":"Marek S, Tervo-Clemmens B, Calabro FJ, Montez DF, Kay BP, Hatoum AS, Donohue MR, Foran W, Miller RL, Hendrickson TJ, Malone SM, Kandala S, Feczko E, Miranda-Dominguez O, Graham AM, Earl EA, Perrone AJ, Cordova M, Doyle O, \u2026 Dosenbach NUF (2022) Reproducible brain-wide association studies require thousands of individuals. Nature 603:654\u2013660 https:\/\/doi.org\/10.1038\/s41586-022-04492-9","DOI":"10.1038\/s41586-022-04492-9"},{"key":"6788_CR61","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1177\/02698811211050556","volume":"36","author":"J Marschall","year":"2022","unstructured":"Marschall J, Fejer G, Lempe P, Prochazkova L, Kuchar M, Hajkova K, van Elk M (2022) Psilocybin microdosing does not affect emotion-related symptoms and processing: A preregistered field and lab-based study. J Psychopharmacol 36:97\u2013113. https:\/\/doi.org\/10.1177\/02698811211050556","journal-title":"J Psychopharmacol"},{"key":"6788_CR62","doi-asserted-by":"publisher","unstructured":"McIntyre RS, Alsuwaidan M, Baune BT, Berk M, Demyttenaere K, Goldberg JF, Gorwood P, Ho R, Kasper S, Kennedy SH, Ly-Uson J, Mansur RB, McAllister-Williams RH, Murrough JW, Nemeroff CB, Nierenberg AA, Rosenblat JD, Sanacora G, Schatzberg AF, \u2026 Maj M (2023) Treatment-resistant depression: definition, prevalence, detection, management, and investigational interventions. World Psychiatry 22:394\u2013412. https:\/\/doi.org\/10.1002\/WPS.21120","DOI":"10.1002\/WPS.21120"},{"key":"6788_CR63","doi-asserted-by":"publisher","first-page":"215","DOI":"10.3390\/PSYCHOACTIVES3020014","volume":"3","author":"D Meling","year":"2024","unstructured":"Meling D, Ehrenkranz R, Nayak SM, Aicher HD, Funk X, van Elk M, Graziosi M, Bauer PR, Scheidegger M, Yaden DB (2024) Mind the psychedelic hype: Characterizing the risks and benefits of psychedelics for depression. Psychoactives 3:215\u2013234. https:\/\/doi.org\/10.3390\/PSYCHOACTIVES3020014","journal-title":"Psychoactives"},{"key":"6788_CR64","doi-asserted-by":"publisher","first-page":"e078084","DOI":"10.1136\/BMJ-2023-078084","volume":"385","author":"AM Metaxa","year":"2024","unstructured":"Metaxa AM, Clarke M (2024) Efficacy of psilocybin for treating symptoms of depression: systematic review and meta-analysis. BMJ 385:e078084. https:\/\/doi.org\/10.1136\/BMJ-2023-078084","journal-title":"BMJ"},{"key":"6788_CR65","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/S12888-018-1824-6\/TABLES\/3","volume":"18","author":"TI Michaels","year":"2018","unstructured":"Michaels TI, Purdon J, Collins A, Williams MT (2018) Inclusion of people of color in psychedelic-assisted psychotherapy: A review of the literature. BMC Psychiatry 18:1\u201314. https:\/\/doi.org\/10.1186\/S12888-018-1824-6\/TABLES\/3","journal-title":"BMC Psychiatry"},{"key":"6788_CR66","doi-asserted-by":"publisher","first-page":"3243","DOI":"10.1038\/s41380-022-01661-0","volume":"28","author":"J Moncrieff","year":"2023","unstructured":"Moncrieff J, Cooper RE, Stockmann T, Amendola S, Hengartner MP, Horowitz MA (2023) The serotonin theory of depression: a systematic umbrella review of the evidence. Mol Psychiatry 28:3243\u20133256. https:\/\/doi.org\/10.1038\/s41380-022-01661-0","journal-title":"Mol Psychiatry"},{"key":"6788_CR67","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1192\/BJP.134.4.382","volume":"134","author":"SA Montgomery","year":"1979","unstructured":"Montgomery SA, \u00c5sberg M (1979) A new depression scale designed to be sensitive to change. Br J Psychiatry 134:382\u2013389. https:\/\/doi.org\/10.1192\/BJP.134.4.382","journal-title":"Br J Psychiatry"},{"key":"6788_CR68","doi-asserted-by":"publisher","first-page":"788155","DOI":"10.3389\/FPHAR.2021.788155\/BIBTEX","volume":"12","author":"R Murphy","year":"2022","unstructured":"Murphy R, Kettner H, Zeifman R, Giribaldi B, Kartner L, Martell J, Read T, Murphy-Beiner A, Baker-Jones M, Nutt D, Erritzoe D, Watts R, Carhart-Harris R (2022) Therapeutic alliance and rapport modulate responses to psilocybin assisted therapy for depression. Front Pharmacol 12:788155. https:\/\/doi.org\/10.3389\/FPHAR.2021.788155\/BIBTEX","journal-title":"Front Pharmacol"},{"key":"6788_CR69","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1080\/17512433.2023.2279736","volume":"16","author":"SD Muthukumaraswamy","year":"2023","unstructured":"Muthukumaraswamy SD (2023) Overcoming blinding confounds in psychedelic randomized controlled trials using biomarker driven causal mediation analysis. Expert Rev Clin Pharmacol 16:1163\u20131173. https:\/\/doi.org\/10.1080\/17512433.2023.2279736","journal-title":"Expert Rev Clin Pharmacol"},{"key":"6788_CR70","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1080\/17512433.2021.1933434","volume":"14","author":"SD Muthukumaraswamy","year":"2021","unstructured":"Muthukumaraswamy SD, Forsyth A, Lumley T (2021) Blinding and expectancy confounds in psychedelic randomized controlled trials. Expert Rev Clin Pharmacol 14:1133\u20131152. https:\/\/doi.org\/10.1080\/17512433.2021.1933434","journal-title":"Expert Rev Clin Pharmacol"},{"key":"6788_CR71","doi-asserted-by":"publisher","first-page":"47000","DOI":"10.4088\/JCP.22R14518","volume":"84","author":"SM Nayak","year":"2023","unstructured":"Nayak SM, Bradley MK, Kleykamp BA, Strain EC, Dworkin RH, Johnson MW (2023) Control conditions in randomized trials of psychedelics: An ACTTION systematic review. J Clin Psychiatry 84:47000. https:\/\/doi.org\/10.4088\/JCP.22R14518","journal-title":"J Clin Psychiatry"},{"key":"6788_CR72","doi-asserted-by":"publisher","unstructured":"Nejstgaard CH, Bero L, Hr\u00f3bjartsson A, J\u00f8rgensen AW, J\u00f8rgensen KJ, Le M, Lundh A (2020) Association between conflicts of interest and favourable recommendations in clinical guidelines, advisory committee reports, opinion pieces, and narrative reviews: systematic review. BMJ 371 https:\/\/doi.org\/10.1136\/BMJ.M4234","DOI":"10.1136\/BMJ.M4234"},{"key":"6788_CR73","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/J.PHARMTHERA.2003.11.002","volume":"101","author":"DE Nichols","year":"2004","unstructured":"Nichols DE (2004) Hallucinogens. Pharmacol Ther 101:131\u2013181. https:\/\/doi.org\/10.1016\/J.PHARMTHERA.2003.11.002","journal-title":"Pharmacol Ther"},{"key":"6788_CR74","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1177\/0269881118780612","volume":"32","author":"T Noorani","year":"2018","unstructured":"Noorani T, Garcia-Romeu A, Swift TC, Griffiths RR, Johnson MW (2018) Psychedelic therapy for smoking cessation: Qualitative analysis of participant accounts. J Psychopharmacol 32:756\u2013769. https:\/\/doi.org\/10.1177\/0269881118780612","journal-title":"J Psychopharmacol"},{"key":"6788_CR75","doi-asserted-by":"publisher","first-page":"109127","DOI":"10.1016\/J.NEUROPHARM.2022.109127","volume":"214","author":"CE Ortiz","year":"2022","unstructured":"Ortiz CE, Dourron HM, Sweat NW, Garcia-Romeu A, MacCarthy S, Anderson BT, Hendricks PS (2022) Special considerations for evaluating psilocybin-facilitated psychotherapy in vulnerable populations. Neuropharmacology 214:109127. https:\/\/doi.org\/10.1016\/J.NEUROPHARM.2022.109127","journal-title":"Neuropharmacology"},{"key":"6788_CR76","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1111\/J.1749-6632.1957.TB40738.X","volume":"66","author":"H Osmond","year":"1957","unstructured":"Osmond H (1957) A review of the clinical effects of psychotomimetic agents. Ann N Y Acad Sci 66:418\u2013434. https:\/\/doi.org\/10.1111\/J.1749-6632.1957.TB40738.X","journal-title":"Ann N Y Acad Sci"},{"key":"6788_CR77","doi-asserted-by":"publisher","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl E A, Brennan SE, Chou R, Glanville J, Grimshaw JM, Hr\u00f3bjartsson A, Lalu MM, Li T, Loder EW, Mayo-Wilson E, McDonald S, \u2026 Moher D (2021) The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. PLoS Med 18(3):1\u201315 https:\/\/doi.org\/10.1371\/JOURNAL.PMED.1003583","DOI":"10.1371\/JOURNAL.PMED.1003583"},{"key":"6788_CR78","doi-asserted-by":"publisher","first-page":"e32","DOI":"10.1192\/BJO.2023.627","volume":"10","author":"S Pappa","year":"2024","unstructured":"Pappa S, Shah M, Young S, Anwar T, Background TM (2024) Care pathways, prescribing practices and treatment outcomes in major depressive disorder and treatment-resistant depression: retrospective, population-based cohort study. Bjpsych Open 10:e32. https:\/\/doi.org\/10.1192\/BJO.2023.627","journal-title":"Bjpsych Open"},{"key":"6788_CR79","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/J.EURONEURO.2023.07.011","volume":"76","author":"N Perez","year":"2023","unstructured":"Perez N, Langlest F, Mallet L, De Pieri M, Sentissi O, Thorens G, Seragnoli F, Zullino D, Kirschner M, Kaiser S, Solmi M, Sab\u00e9 M (2023) Psilocybin-assisted therapy for depression: A systematic review and dose-response meta-analysis of human studies. Eur Neuropsychopharmacol 76:61\u201376. https:\/\/doi.org\/10.1016\/J.EURONEURO.2023.07.011","journal-title":"Eur Neuropsychopharmacol"},{"issue":"4","key":"6788_CR80","doi-asserted-by":"publisher","first-page":"e208109","DOI":"10.1212\/WNL.0000000000208109\/SUPPL_FILE\/SUPPLEMENTARY_DATA1.PDF","volume":"102","author":"JH Pizer","year":"2024","unstructured":"Pizer JH, Aita SL, Myers MA, Hawley NA, Ikonomou VC, Brasil KM, Hernandez KA, Pettway EC, Owen T, Borgogna NC, Smitherman TA, Hill BD (2024) Neuropsychological function in migraine headaches. Neurology 102(4):e208109. https:\/\/doi.org\/10.1212\/WNL.0000000000208109\/SUPPL_FILE\/SUPPLEMENTARY_DATA1.PDF","journal-title":"Neurology"},{"key":"6788_CR81","doi-asserted-by":"publisher","unstructured":"Preller KH, Vollenweider FX (2016) Phenomenology, Structure, and Dynamic of Psychedelic States. In Behavioral Neurobiology of Psychedelic Drugs (pp. 221\u2013256). Springer Berlin Heidelberg. https:\/\/doi.org\/10.1007\/7854_2016_459","DOI":"10.1007\/7854_2016_459"},{"key":"6788_CR82","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/J.JAD.2012.01.030","volume":"140","author":"J Price","year":"2012","unstructured":"Price J, Cole V, Doll H, Goodwin GM (2012) The Oxford questionnaire on the emotional side- effects of antidepressants (OQuESA): Development, validity, reliability and sensitivity to change. J Affect Disord 140:66\u201374. https:\/\/doi.org\/10.1016\/J.JAD.2012.01.030","journal-title":"J Affect Disord"},{"key":"6788_CR83","doi-asserted-by":"publisher","unstructured":"Raison CL, Sanacora G, Woolley J, Heinzerling K, Dunlop BW, Brown RT, Kakar R, Hassman M, Trivedi RP, Robison R, Gukasyan N, Nayak SM, Hu X, O\u2019Donnell KC, Kelmendi B, Sloshower J, Penn AD, Bradley E, Kelly DF, \u2026 Griffiths RR (2023) Single-dose psilocybin treatment for major depressive disorder: A randomized clinical trial. JAMA 330:843\u2013853. https:\/\/doi.org\/10.1001\/JAMA.2023.14530","DOI":"10.1001\/JAMA.2023.14530"},{"key":"6788_CR84","doi-asserted-by":"publisher","first-page":"10187","DOI":"10.4088\/JCP.12R08046","volume":"74","author":"JG Reid","year":"2013","unstructured":"Reid JG, Gitlin MJ, Altshuler LL (2013) Lamotrigine in psychiatric disorders. J Clin Psychiatry 74:10187. https:\/\/doi.org\/10.4088\/JCP.12R08046","journal-title":"J Clin Psychiatry"},{"key":"6788_CR85","doi-asserted-by":"publisher","first-page":"103818","DOI":"10.1016\/J.DRUDIS.2023.103818","volume":"28","author":"TG Rhee","year":"2023","unstructured":"Rhee TG, Davoudian PA, Sanacora G, Wilkinson ST (2023) Psychedelic renaissance: Revitalized potential therapies for psychiatric disorders. Drug Discovery Today 28:103818. https:\/\/doi.org\/10.1016\/J.DRUDIS.2023.103818","journal-title":"Drug Discovery Today"},{"key":"6788_CR86","doi-asserted-by":"publisher","unstructured":"Rosenblat JD, Meshkat S, Doyle Z, Kaczmarek E, Brudner RM, Kratiuk K, Mansur RB, Schulz- Quach C, Sethi R, Abate A, Ali S, Bawks J, Blainey MG, Brietzke E, Cronin V, Danilewitz J, Dhawan S, Di Fonzo A, Di Fonzo M, \u2026 McIntyre RS (2024) Psilocybin-assisted psychotherapy for treatment resistant depression: A randomized clinical trial evaluating repeated doses of psilocybin. Med 5:190\u2013200.e5. https:\/\/doi.org\/10.1016\/j.medj.2024.01.005","DOI":"10.1016\/j.medj.2024.01.005"},{"key":"6788_CR87","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1177\/0269881116675512\/ASSET\/IMAGES\/LARGE\/10.1177_0269881116675512-FIG7.JPEG","volume":"30","author":"S Ross","year":"2016","unstructured":"Ross S, Bossis A, Guss J, Agin-Liebes G, Malone T, Cohen B, Mennenga SE, Belser A, Kalliontzi K, Babb J, Su Z, Corby P, Schmidt BL (2016) Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: A randomized controlled trial. J Psychopharmacol 30:1165\u20131180. https:\/\/doi.org\/10.1177\/0269881116675512\/ASSET\/IMAGES\/LARGE\/10.1177_0269881116675512-FIG7.JPEG","journal-title":"J Psychopharmacol"},{"issue":"2","key":"6788_CR88","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1192\/BJB.2023.28","volume":"48","author":"JJ Rucker","year":"2023","unstructured":"Rucker JJ (2023) Evidence versus expectancy: the development of psilocybin therapy. BJPsych Bull 48(2):110\u2013117. https:\/\/doi.org\/10.1192\/BJB.2023.28","journal-title":"BJPsych Bull"},{"key":"6788_CR89","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/S0006-3223(02)01866-8","volume":"54","author":"AJ Rush","year":"2003","unstructured":"Rush AJ, Trivedi MH, Ibrahim HM, Carmody TJ, Arnow B, Klein DN, Markowitz JC, Ninan PT, Kornstein S, Manber R, Thase ME, Kocsis JH, Keller MB (2003) The 16-Item quick inventory of depressive symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS- SR): a psychometric evaluation in patients with chronic major depression. Biol Psychiat 54:573\u2013583. https:\/\/doi.org\/10.1016\/S0006-3223(02)01866-8","journal-title":"Biol Psychiat"},{"key":"6788_CR90","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1001\/ARCHPSYC.1973.01750360040005","volume":"28","author":"C Savage","year":"1973","unstructured":"Savage C, Mccabe OL (1973) Residential psychedelic (LSD) therapy for the narcotic addict: A controlled study. Arch Gen Psychiatry 28:808\u2013814. https:\/\/doi.org\/10.1001\/ARCHPSYC.1973.01750360040005","journal-title":"Arch Gen Psychiatry"},{"key":"6788_CR91","doi-asserted-by":"publisher","first-page":"323606","DOI":"10.3389\/FPHAR.2018.00733\/BIBTEX","volume":"9","author":"EE Schenberg","year":"2018","unstructured":"Schenberg EE (2018) Psychedelic-assisted psychotherapy: A paradigm shift in psychiatric research and development. Front Pharmacol 9:323606. https:\/\/doi.org\/10.3389\/FPHAR.2018.00733\/BIBTEX","journal-title":"Front Pharmacol"},{"key":"6788_CR92","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/J.NEUROIMAGE.2019.04.009","volume":"196","author":"L Smigielski","year":"2019","unstructured":"Smigielski L, Scheidegger M, Kometer M, Vollenweider FX (2019) Psilocybin-assisted mindfulness training modulates self-consciousness and brain default mode network connectivity with lasting effects. Neuroimage 196:207\u2013215. https:\/\/doi.org\/10.1016\/J.NEUROIMAGE.2019.04.009","journal-title":"Neuroimage"},{"key":"6788_CR93","doi-asserted-by":"publisher","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, Elbers RG, Blencowe NS, Boutron I, Cates CJ, Cheng HY, Corbett MS, Eldridge SM, Emberson JR, Hern\u00e1n MA, Hopewell S, Hr\u00f3bjartsson A, Junqueira DR, J\u00fcni P, Kirkham JJ, Lasserson T, Li T, \u2026 Higgins JPT (2019) RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ 366. https:\/\/doi.org\/10.1136\/BMJ.L4898","DOI":"10.1136\/BMJ.L4898"},{"key":"6788_CR94","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1136\/MEDETHICS-2021-107262","volume":"48","author":"D Strauss","year":"2022","unstructured":"Strauss D, De La Salle S, Sloshower J, Williams MT (2022) Research abuses against people of colour and other vulnerable groups in early psychedelic research. J Med Ethics 48:728\u2013737. https:\/\/doi.org\/10.1136\/MEDETHICS-2021-107262","journal-title":"J Med Ethics"},{"key":"6788_CR95","doi-asserted-by":"publisher","unstructured":"Strickland JC, Johnson MW (2022) Human behavioral pharmacology of psychedelics. In J. Li (Ed.), Behavioral Pharmacology of Drug Abuse: Current Status (pp. 105\u2013132). Academic Press. https:\/\/doi.org\/10.1016\/bs.apha.2021.10.003","DOI":"10.1016\/bs.apha.2021.10.003"},{"key":"6788_CR96","doi-asserted-by":"publisher","first-page":"344412","DOI":"10.3389\/FPHAR.2018.00172\/BIBTEX","volume":"9","author":"LR Swanson","year":"2018","unstructured":"Swanson LR (2018) Unifying theories of psychedelic drug effects. Front Pharmacol 9:344412. https:\/\/doi.org\/10.3389\/FPHAR.2018.00172\/BIBTEX","journal-title":"Front Pharmacol"},{"issue":"10","key":"6788_CR97","doi-asserted-by":"publisher","first-page":"4305","DOI":"10.1017\/S0033291723001058","volume":"53","author":"T Taillefer de Laportali\u00e8re","year":"2023","unstructured":"Taillefer de Laportali\u00e8re T, Jullien A, Yrondi A, Cestac P, Montastruc F (2023) Reporting of harms in clinical trials of esketamine in depression: a systematic review. Psychol Med 53(10):4305\u20134315. https:\/\/doi.org\/10.1017\/S0033291723001058","journal-title":"Psychol Med"},{"key":"6788_CR98","doi-asserted-by":"publisher","first-page":"204512532311984","DOI":"10.1177\/20451253231198466","volume":"13","author":"M van Elk","year":"2023","unstructured":"van Elk M, Fried EI (2023) History repeating: guidelines to address common problems in psychedelic science. Ther Adv Psychopharmacol 13:20451253231198464. https:\/\/doi.org\/10.1177\/20451253231198466","journal-title":"Ther Adv Psychopharmacol"},{"key":"6788_CR99","doi-asserted-by":"publisher","first-page":"101809","DOI":"10.1016\/j.eclinm.2022.101809","volume":"56","author":"R von Rotz","year":"2023","unstructured":"von Rotz R, Schindowski EM, Jungwirth J, Schuldt A, Rieser NM, Zahoranszky K, Seifritz E, Nowak A, Nowak P, J\u00e4ncke L, Preller KH, Vollenweider FX (2023) Single-dose psilocybin-assisted therapy in major depressive disorder: A placebo-controlled, double-blind, randomised clinical trial. The Lancet 56:101809. https:\/\/doi.org\/10.1016\/j.eclinm.2022.101809","journal-title":"The Lancet"},{"issue":"3","key":"6788_CR100","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1002\/WPS.20238","volume":"14","author":"BE Wampold","year":"2015","unstructured":"Wampold BE (2015) How important are the common factors in psychotherapy? An Update. World Psychiatry 14(3):270\u2013277. https:\/\/doi.org\/10.1002\/WPS.20238","journal-title":"World Psychiatry"},{"key":"6788_CR101","doi-asserted-by":"publisher","first-page":"152303","DOI":"10.1016\/J.COMPPSYCH.2022.152303","volume":"115","author":"M Wiz\u0142a","year":"2022","unstructured":"Wiz\u0142a M, Kraus SW, Lewczuk K (2022) Perspective: Can psychedelic-assisted therapy be a promising aid in compulsive sexual behavior disorder treatment? Compr Psychiatry 115:152303. https:\/\/doi.org\/10.1016\/J.COMPPSYCH.2022.152303","journal-title":"Compr Psychiatry"},{"key":"6788_CR102","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1001\/JAMAPSYCHIATRY.2022.2546","volume":"79","author":"DB Yaden","year":"2022","unstructured":"Yaden DB, Potash JB, Griffiths RR (2022) Preparing for the bursting of the psychedelic hype bubble. JAMA Psychiat 79:943\u2013944. https:\/\/doi.org\/10.1001\/JAMAPSYCHIATRY.2022.2546","journal-title":"JAMA Psychiat"},{"key":"6788_CR103","doi-asserted-by":"publisher","first-page":"938","DOI":"10.3390\/JCM11040938\/S1","volume":"11","author":"CL Yu","year":"2022","unstructured":"Yu CL, Liang CS, Yang FC, Tu YK, Hsu CW, Carvalho AF, Stubbs B, Thompson T, Tsai CK, Yeh TC, Yang SN, Shin JI, Chu CS, Tseng PT, Su KP (2022) Trajectory of antidepressant effects after single-or two-dose administration of psilocybin: A systematic review and multivariate meta-analysis. J Clin Med 11:938. https:\/\/doi.org\/10.3390\/JCM11040938\/S1","journal-title":"J Clin Med"},{"key":"6788_CR104","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1176\/appi.ajp.2018.17111282","volume":"175","author":"Z Zeier","year":"2018","unstructured":"Zeier Z, Carpenter LL, Kalin NH, Rodriguez CI, McDonald WM, Widge AS, Nemeroff CB (2018) Clinical implementation of pharmacogenetic decision support tools for antidepressant drug prescribing. Am J Psychiatry 175:873\u2013886. https:\/\/doi.org\/10.1176\/appi.ajp.2018.17111282","journal-title":"Am J Psychiatry"},{"key":"6788_CR105","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/J.JAD.2023.04.105","volume":"334","author":"RJ Zeifman","year":"2023","unstructured":"Zeifman RJ, Wagner AC, Monson CM, Carhart-Harris RL (2023) How does psilocybin therapy work? An exploration of experiential avoidance as a putative mechanism of change. J Affect Disord 334:100\u2013112. https:\/\/doi.org\/10.1016\/J.JAD.2023.04.105","journal-title":"J Affect Disord"},{"key":"6788_CR106","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1111\/J.1600-0447.1983.TB09716.X","volume":"67","author":"AS Zigmond","year":"1983","unstructured":"Zigmond AS, Snaith RP (1983) The hospital anxiety and depression scale. Acta Psychiatr Scand 67:361\u2013370. https:\/\/doi.org\/10.1111\/J.1600-0447.1983.TB09716.X","journal-title":"Acta Psychiatr Scand"}],"updated-by":[{"DOI":"10.1007\/s00213-025-06818-7","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,5,17]],"date-time":"2025-05-17T00:00:00Z","timestamp":1747440000000}}],"container-title":["Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-025-06788-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00213-025-06788-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-025-06788-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T08:24:15Z","timestamp":1758270255000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00213-025-06788-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,23]]},"references-count":106,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["6788"],"URL":"https:\/\/doi.org\/10.1007\/s00213-025-06788-w","relation":{},"ISSN":["0033-3158","1432-2072"],"issn-type":[{"value":"0033-3158","type":"print"},{"value":"1432-2072","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,23]]},"assertion":[{"value":"27 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 May 2025","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s00213-025-06818-7","URL":"https:\/\/doi.org\/10.1007\/s00213-025-06818-7","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study did not involve living subjects and therefore was exempt from ethical board review","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"No consent to participate was administered as there were no living subjects.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"All authors consent to publication.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publication"}},{"value":"All authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interest"}}]}}